AI modeling transforms drug development from a numbers game of screening millions of compounds to an engineering discipline. Researchers can model molecular systems upfront, understand key parameters, and design solutions for a specific problem, turning a costly screening process into a rapid, targeted design cycle.

The transition to an engineering discipline in drug discovery, analogous to aeronautics, means using powerful in silico models to get much closer to a final product before physical testing. This reduces reliance on iterative, expensive, and time-consuming wet lab experiments.

Eroom's Law (Moore's Law reversed) shows rising R&D costs without better success rates. A key culprit may be the obsession with mechanistic understanding. AI 'black box' models, which prioritize predictive results over explainability, could break this expensive bottleneck and accelerate the discovery of effective treatments.

The supply chain for neurons is not the main problem; they can be produced easily. The true challenge and next major milestone is "learning in vitro"—discovering the principles to program neural networks to perform consistent, desired computations like recognizing images or executing logic.

Instead of screening billions of nature's existing proteins (a search problem), AI-powered de novo design creates entirely new proteins for specific functions from scratch. This moves the paradigm from hoping to find a match to intentionally engineering the desired molecule.

Beyond accelerating timelines, AI's real value lies in its ability to design molecules for targets previously considered 'hard-to-drug.' These models operate on different principles than traditional lab methods and are indifferent to historical challenges, opening up entirely new therapeutic possibilities.

Patrick Collison believes we can finally cure complex diseases because biology now has a complete 'Turing loop': advanced sequencing to 'read' biological data, neural networks to 'think' about it, and CRISPR to 'write' changes by perturbing cells. This combination provides the necessary toolset for breakthroughs.

Songyee Yoon applied her Ph.D. in computational neuroscience not to study the brain with computers, but to use principles of human perception to build better technology, such as more effective signal processing algorithms and user interfaces.

A major biotech revolution is underway as AI now enables effective 'in silico' (simulated) experiments. This shift from physical "wet labs" to cheap, infinitely scalable simulations drastically cuts time and cost for drug discovery, making audacious goals like curing cancer scientifically plausible.